更新
3月11日 - ** 生物技术公司卡拉生物KALA.O股价上涨50%至42美分
** 该公司称将在两周内推出首个商业人工智能平台 "Researgency.ai"，业务范围将扩展到药物开发之外。
** KALA的Researgency.ai旨在实现常规生物技术任务的自动化，如文书工作、合规性工作和研究监控。
** 该公司表示，首个定制人工智能代理将在 14 天内交付，预计该平台将带来经常性收入
** 该公司表示，该平台的推出标志着该公司已转向将生物制剂管道与可扩展的人工智能服务相结合的双重模式
** 2025 年股价下跌约 92%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.